Ventripoint VMS™ Heart Analysis System Cleared by USFDA

Ventripoint Diagnostics Ltd.’s (TSXV:VPT) VMS™ heart analysis system has been granted clearance by the US Food and Drug Administration for use in patients with Pulmonary Arterial Hypertension. The VMS heart analysis system enables physicians to quickly and non-invasively determine the size and function of the right heart.

The VMS™ is approved for clinical use in PAH patients in Canada and Europe, and now in the United States.

Ventripoint President and CEO, George Adams, said:

We are pleased to affirm the FDA’s marketing clearance today for the VMS – the first ultrasound method to give accurate right ventricle functional measurements using conventional 2D ultrasound. People with PAH require frequent monitoring and adjustments to their treatments, which requires a detailed assessment of right heart function.

Click here to read the Ventripoint Diagnostics Ltd. (TSXV:VPT) press release